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1. Background Information:
Hypoplastic left heart syndrome (HLHS) collectively refers to a range of congenital heart
defects, all involving some degree of left ventricular hypoplasia, or underdevelopment of the left
ventricle.1,2 Additionally, HLHS often involves coarctation of the aorta,1 and can also include
hypoplasia of the ascending aorta, as well as mitral and/or aortic valve stenosis or atresia.1,2
HLHS is extremely rare, as it has been reported to occur in only 1 in 5000 live births each year.2
The cause of HLHS is currently unknown, however much research is being done to discover how
and why these defects occur.
HLHS is known to be familially inherited in some instances and is also associated with
many well-characterized genetic disorders, including Holt-Oram syndrome, Turner’s syndrome,
Noonan syndrome, Smith-Lemli-Opitz syndrome, as well as trisomies 13, 18, and 21.1,2
Additionally, an autosomal recessive pattern of inheritance has been found amongst some
siblings, however, no specific genes have been implicated.2 Incidence of HLHS also varies
significantly in certain geographical regions and some studies have found a seasonal correlation
in HLHS, indicating a possible environmental cause.2,3
2. Hypothesis and Rationale:
A study done in 2011 by
Eghtesady, et. al. found a moderate
to strong correlation between
seasonality and HLHS.
Interestingly, among the four leftsided congenital heart defects
studied at the time, HLHS was the
only disease that showed such a
correlation (Figure 2.1). HLHS
was found to be more prevalent in
babies born during the early
summer months, particularly
during the month of June.3 If these
were full-term pregnancies, infants
born at this time of year would
have been conceived during the
fall, around September, right
when the seasons are
transitioning.

Figure 2.1. Seasonality of HLHS – incidence of HLHS was
found to be increased in the summer months, and decreased
in the winter months. This seasonal correlation was not
found with any other left heart defects. (Adapted from:
Eghtesady, P., Brar, A., & Hall, M. Seasonality of hypoplastic left heart
syndrome in the United States: A 10-year time--series analysis. Journal of
Thoracic and CV Surgery. 2011; 432-438.)

During the transition of seasons, symptoms of allergies, or even the common cold, may
start to form. These symptoms could lead mothers to take medications, such as decongestants, to
combat these seasonal illnesses. A common over-the-counter medication used is
pseudoephedrine, also known as Sudafed, a decongestant. Studies have found that 25% of
women are exposed to pseudoephedrine during their pregnancy.4 In order to be effective,
pseudoephedrine acts on the α1 and the β2 receptors found on the walls of the blood vessels.
When pseudoephedrine binds to these receptors, it initiates the α1 pathway in which the second
messenger, DAG, activates Protein Kinase C (PKC). PKC then causes phosphorylation of a
protein that promotes the constriction of the smooth muscle that makes up blood vessels. When
this constriction occurs, blood flow is limited.5

Figure 2.2. Mechanism of PKC activation by pseudoephedrine via the GQ pathway.

PKC also plays a role in a number of cell signaling pathways including pathways that are
responsible for controlling expression of some Tbx genes, particularly Tbx2 (Figure 2.2).6 Tbx
genes code for a family of transcription factors, the T-box proteins, which are crucial for
determination of cell differentiation in early embryogenesis, including cardiogenesis. Various Tbox proteins play a role in initial specification of the cardiac mesoderm, regionalization of the
primitive heart tube into chamber and non-chamber cardium, recruitment of second heart field
cells, and formation of the valves and septa.7
Tbx mutations have already been identified as the cause for many other wellcharacterized genetic conditions involving congenital heart defects, including some of the
diseases previously mentioned to be frequently associated with HLHS. For example, Holt-Oram
syndrome is caused by a heterozygous mutation in the Tbx5 gene.7 Heterozygous mutation of

another gene, Tbx1 has been
implicated as the cause of
DiGeorge’s syndrome, also
called 22q11.2 deletion
syndrome.7,8 Interestingly,
mosaic 22q11 deletion has also
been reported in many HLHS
cases.2
Evidence has also shown
that a specific form of HLHS aortic atresia with a hypoplastic
but perforate mitral valve - is 5570% more common in males.2
This increased prevalence in
males could indicate a sex-linked
gene as the cause of that form.
Tbx22 is found on the X
chromosome, and its mutation
has been shown to cause birth
defects.7 Although no heart
Figure 3.1. TBX2 represses the activity of TBX1, TBX5, and
defects have been associated with
TBX20, leading to decreased expression of chamber
Tbx22 mutation, based on the
myocardial genes.
complex roles T-box proteins
play in embryogenesis, it is possible that TBX22 still affects cardiogenesis, and ultimately left
heart development, in some manner. Additionally, there could be another sex-linked Tbx gene
that is currently unidentified.
TBX2 is especially important, as this protein is known to have an effect on other T-box
proteins. TBX2 is involved in a pathway that actually represses the activity of TBX1, TBX5,
and TBX20, thus preventing expression of genes that lead to heart chamber formation (Figure
3.1).8 It is therefore possible that overexpression of TBX2 can lead to an increase in this
repressive mechanism. As mentioned previously, TBX5 and TBX20 are important in left heart
development and it is therefore likely increased repression of TBX5 and TBX20 will specifically
cause decreased formation of the left heart and HLHS.
3. Significance and Innovation:
In order to test this hypothesis, a large scale epidemiological study would need to be done
that monitors the use of decongestants during pregnancy, and examines any correlations between
their use and the occurrence of HLHS. If a correlation between pseudoephedrine usage during
pregnancy and fetal HLHS was found, medications containing pseudoephedrine would need to
be more clearly labeled as a possible cause for birth defects. Until definitive studies are done, we
would strongly discourage pregnant women to take these medications during pregnancy. One
reason the effects of decongestants on HLHS has not been researched heavily in the past, is
because pregnant women are typically excluded from clinical trials.6 Therefore, we suggest
using an animal model to monitor the effects of decongestant use on PKC levels and
cardiogenesis.
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